FDA Orders Updated Drug Labels for Actos, Pioglitazone-Based Medications
The Food and Drug Administration (FDA) recently required drug manufacturers to change the drug labels on Actos and other pioglitazone-based medications to notify patients of the very serious risks associated with taking pioglitazone treatments for longer than one year.
The FDA’s changed regulation underscores an increasing awareness within the medical community that Actos and other pioglitazone medications pose serious risks. Additionally, this shift in policy raises important legal questions, including whether the drug manufacturer appropriately warned physicians and patients about the risk of pioglitazone when it was first released to the market.
Tragically, thousands of Americans have suffered physical pain, emotional suffering, and financial loss as a result of bladder cancer and other pioglitazone-related ailments. Fears Nachawati, a law firm specializing in dangerous drugs, protects victims from the misconduct of major drug manufacturers. If you’ve been injured, we can protect you, too. For your free consultation, call 1.866.545.8364 or email email@example.com.